Celaid Raises JPY400M as Shionogi, Teikoku Ventures Back US Trial Push
Image
Tokyo – October 04, 2026 -- Celaid Therapeutics Inc. has completed the second close of its Series B financing round, raising JPY 400 million (approximately USD 2.6 million) with new backing from Shionogi & Co., Ltd. and Teikoku Ventures, Inc.
Shionogi and Teikoku Ventures enter as new strategic investors
The two pharmaceutical-linked investors cited the development progress and therapeutic potential of CLD-001, Celaid's lead hematopoietic stem cell (HSC) therapy candidate, as the basis for their investment. Teikoku Ventures operates as the corporate venture capital arm of the TEIKOKU SEIYAKU Group.
AMED advances Celaid to Stage 3 funding under startup ecosystem program
Celaid also passed the second stage-gate review of AMED's "Strengthening Program for Pharmaceutical Startup Ecosystem,